Browsing by Author "Sohail, Amir Humza"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Early and Late Readmissions of Radiation Proctitis in the United States: Are We Getting Better?
    (MDPI, 2024-01-12) Dahiya, Dushyant Singh; Pinnam, Bhanu Siva Mohan; Ishaya, Michelle; Chandan, Saurabh; Gangwani, Manesh Kumar; Singh, Sahib; Ali, Hassam; Sohail, Amir Humza; Canakis, Andrew; Ramai, Daryl; Zelt, Christina; Inamdar, Sumant; Al-Haddad, Mohammad; Rojas-DeLeon, Mariajose; Sharma, Neil R.; Medicine, School of Medicine
    Background/Aims: Radiation proctitis (RP), a well-known complication of pelvic radiation therapy, may lead to recurrent hospitalizations. We aimed to assess readmissions of RP in the United States. Methods: We analyzed the Nationwide Readmission Database from 2016 to 2020 to identify all 30-, 60-, and 90-day readmissions of RP in the United States. Hospitalization characteristics, predictors, clinical outcomes, and healthcare burdens were assessed. Results: From 2016 to 2020, we noted a declining trend of 30-, 60-, and 90-day readmissions of RP in the US. However, the all-cause 30-, 60-, and 90-day readmission rates of RP were still high at 13.7%, 19.4%, and 23.16%, respectively. On readmission, RP was identified as the admitting diagnosis in only 20.61%, 17.87%, and 15.76% of 30-, 60-, and 90-day readmissions, respectively. The mean age for all readmissions was 70 years with a significant male dominance. Lower endoscopy at index admission reduced the risk of readmissions within 90 days, but this was not statistically significant. However, the Charlson Comorbidity Index (CCI) score was an independent predictor of all readmissions. Furthermore, the mean length of stay was 5.57 (95% CI 5.15-6), 5.50 (95% CI 5.12-5.89), and 5.47 (95% CI 5.07-5.87) days and the mean hospitalization charge was USD 60,451 (95% CI USD 54,728-66,174), USD 62,671 (95% CI USD 57,326-68,015), and USD 62,144 (95% CI USD 57,144-67,144) for 30-, 60-, and 90-day readmissions. The all-cause inpatient mortality for 30-, 60-, and 90-day readmissions was 3.58%, 3.89%, and 3.46%, respectively. Conclusions: RP readmissions are a significant healthcare burden. Further efforts must be directed toward improving management strategies to reduce readmission rates.
  • Thumbnail Image
    Item
    Remimazolam for sedation in gastrointestinal endoscopy: A comprehensive review
    (Baishideng, 2024) Dahiya, Dushyant Singh; Kumar, Ganesh; Parsa, Syeda; Gangwani, Manesh Kumar; Ali, Hassam; Sohail, Amir Humza; Alsakarneh, Saqr; Hayat, Umar; Malik, Sheza; Shah, Yash R.; Mohan Pinnam, Bhanu Siva; Singh, Sahib; Mohamed, Islam; Rao, Adishwar; Chandan, Saurabh; Al-Haddad, Mohammad; Medicine, School of Medicine
    Worldwide, a majority of routine endoscopic procedures are performed under some form of sedation to maximize patient comfort. Propofol, benzodiazepines and opioids continue to be widely used. However, in recent years, Remimazolam is gaining immense popularity for procedural sedation in gastrointestinal (GI) endoscopy. It is an ultra-short-acting benzodiazepine sedative which was approved by the Food and Drug Administration in July 2020 for use in procedural sedation. Remimazolam has shown a favorable pharmacokinetic and pharmacodynamic profile in terms of its non-specific metabolism by tissue esterase, volume of distribution, total body clearance, and negligible drug-drug interactions. It also has satisfactory efficacy and has achieved high rates of successful sedation in GI endoscopy. Furthermore, studies have demonstrated that the efficacy of Remimazolam is non-inferior to Propofol, which is currently a gold standard for procedural sedation in most parts of the world. However, the use of Propofol is associated with hemodynamic instability and respiratory depression. In contrast, Remimazolam has lower incidence of these adverse effects intra-procedurally and hence, may provide a safer alternative to Propofol in procedural sedation. In this comprehensive narrative review, highlight the pharmacologic characteristics, efficacy, and safety of Remimazolam for procedural sedation. We also discuss the potential of Remimazolam as a suitable alternative and how it can shape the future of procedural sedation in gastroenterology.